Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy

Leukemia and Lymphoma

Volumn 44, Issue 8, 2003, Pages 1361-1365

  Avilés, Agustin ^a   Cleto, Sergio ^a   Neri, Natividad ^a   Huerta Guzman, Judith ^a   Talavera, Alejandra ^a   Castañeda, Claudia ^a   González, Martha ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

Acute toxicity; Adjuvant radiotherapy; Bleomycin; Chemotherapy; Epirubicin; Hodgkin's disease

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; EBVD PROTOCOL; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; AGRANULOCYTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HODGKIN DISEASE; HUMAN; IATROGENIC DISEASE; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; STATISTICAL ANALYSIS; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; EPIRUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; INFECTION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0038127195     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000067729     Document Type: Article

References (20)

1. Aisenberg, A. (1999) "Problems in Hodgkin's management", Blood 76, 761-779.
2. Engert, A., Wolf, A. and Diehl, V. (1999) "Treatment of advanced Hodgkin's lymphomas. Standard and experimental approaches", Semin. Hematol. 36, 282-289.
3. Avilés, A., Neri, N., Cuadra, L., Alvarado, I. and Cleto, S. (2000) "Second letal events associated with treatment for Hodgkin's disease. A review of 2980 patients treated in a single Mexican Institute", Leuk. Lymphoma 39, 311-319.
4. Avilés, A., Arévila, N., Díaz-Maqueo, J.C., Gómez, T., García, R. and Nambo, M.J. (1993) "Late cardiac toxicity of doxorubicin, epirubicin and mitoxantrone therapy for Hodgkin's disease in adults", Leuk. Lymphoma 11, 275-279.
5. Avilés, A., Guzmán, R., Talavera, A., García, E.L. and Díaz-Maqueo, J.C. (1994) "Randomized study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin and dacarbazine (EBVD) versus mitoxantrone, vinblastine, bleomycin and dacarbazine (MVBD)", Med. Pediatr. Oncol. 22, 168-172.
6. Avilés, A., Soto, B., Guzmán, R., García, E.L., Nambo, M.J. and Díaz-Maqueo, J.C. (1995) "Results of a randomized study of early stage Hodgkin's disease using ABVD, EBVD or MBVD", Med: Pediatr: Oncol. 24, 171-175.
7. Hagemeister, F.B., Cabanillas, F., Velasquez, W., et al. (1990) "NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease", Semin. Oncol. 17(Suppl. 10), 34-40.
8. Hoerni, B., Orgerie, M.B., Bali, E.G.H., et al. (1988) "Nouvelle association d'epirubicine, bleomycine, vinblastine et prednisone (EBVP) avant radiotherapie dans les stades localized de maladie de Hodgkin: Essay de phase II ches 50 malades", Bull. Cancer 75, 789-794.
9. Connors, J.M. and Klimo, P. (1987) "MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease", Semin. Hematol. 24 (Suppl. 1), 35-40.
10. Connors, J.M., Klimo, P., Adams, S., et al. (1997) "Treatment of advanced Hodgkin's disease with chemotherapy. Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD. A Report from the National Cancer Institute of Canada Clinical Trials Group", J. Clin. Oncol. 15, 1638-1641.
11. Viviani, S., Bonadonna, G., Santoro, A., et al. (1996) "Alternating versus hybrid MOPP and ABVD combination in advanced Hodgkin's disease. Ten years results", J. Clin. Oncol. 14, 1421-1430.
12. Somers, R., Carde, P., Henry-Amar, M., et al. (1994) "A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP and ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre--et-Marie-Curie controlled clinical trial", J. Clin. Oncol. 12, 279-287.
13. Klimo, P. and Connors, J.M. (1985) "MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease", J. Clin. Oncol. 3, 1174-1182.
14. Canellos, G.P., Anderson, J.R., Propert, K.J., et al. (1992) "Chemotherapy of advanced Hodgkin's disease with MOPP-ABVD or MOPP alternating with ABVD", N. Engl. J. Med. 327, 1478-1484.
15. Gobbi, P., Pieresca, C., Ghirardelli, M.I., et al. (1998) "Long term results from MOPPEBVCAD chemotherapy with optimal limited radiotherapy in advanced Hodgkin's disease", Blood 91, 2704-2712.
16. Tesh, H., Diehl, V., Lathan, B., et al. (1998) "Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone scheme and adjuvant radiotherapy. A study of the German Hodgkin's Lymphoma Study Group", Blood 92, 4560-4567.
17. Horning, S.J., Rosenberg, S.A. and Hoppe, R.T. (1996) "Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky and advanced Hodgkin's disease", Ann. Oncol. 7 (Suppl. 6), S105-S110.
18. Horning, S.J., Williams, J., Bartlet, N.I., et al. (2000) "Assessment of the Stanford V regimen and consolidative radiotherapy for bulky. and advanced Hodgkin's disease. Eastern Cooperative Oncology Group Pilot Study E 1492", J. Clin. Oncol. 18, 972-977.
19. Avilés, A., Delgado, S., Talavera, A., González, J.L. and Díaz-Maqueo, J.C. (2000) "Adjuvant radiotherapy to initial bulky disease in patients with advanced stage Hodgkin's disease", Hematology 4, 479-485.
20. Avilés, A., Neri, N., García, E.L., Talavera, A. and Díaz-Maqueo, J.C. (2001) "Treatment of refractory Hodgkin's disease with modified Stanford V regimen", Med. Oncol. 18, 261-267.